Optimization of Pharmaceutical R&D Programs and Portfolios Design and Investment Strategy / edited by Zoran Antonijevic.

Very little has been published on optimization of pharmaceutical portfolios. Moreover, most of the published literature comes from the commercial perspective, where probability of technical success (PoS) is treated as fixed, and not as a consequence of development strategy or design. In this book th...

Full description

Saved in:
Bibliographic Details
Corporate Author: SpringerLink (Online service)
Other Authors: Antonijevic, Zoran (Editor)
Format: eBook
Language:English
Published: Cham : Springer International Publishing : Imprint: Springer, 2015.
Edition:1st ed. 2015.
Series:Springer eBook Collection.
Subjects:
Online Access:Click to view e-book
Holy Cross Note:Loaded electronically.
Electronic access restricted to members of the Holy Cross Community.

MARC

LEADER 00000nam a22000005i 4500
001 b3296873
003 MWH
005 20191024231949.0
007 cr nn 008mamaa
008 141010s2015 gw | s |||| 0|eng d
020 |a 9783319090757 
024 7 |a 10.1007/978-3-319-09075-7  |2 doi 
035 |a (DE-He213)978-3-319-09075-7 
050 4 |a E-Book 
072 7 |a KJT  |2 bicssc 
072 7 |a BUS049000  |2 bisacsh 
072 7 |a KJT  |2 thema 
072 7 |a KJMD  |2 thema 
245 1 0 |a Optimization of Pharmaceutical R&D Programs and Portfolios  |h [electronic resource] :  |b Design and Investment Strategy /  |c edited by Zoran Antonijevic. 
250 |a 1st ed. 2015. 
264 1 |a Cham :  |b Springer International Publishing :  |b Imprint: Springer,  |c 2015. 
300 |a VIII, 202 p. 38 illus., 24 illus. in color.  |b online resource. 
336 |a text  |b txt  |2 rdacontent 
337 |a computer  |b c  |2 rdamedia 
338 |a online resource  |b cr  |2 rdacarrier 
347 |a text file  |b PDF  |2 rda 
490 1 |a Springer eBook Collection 
505 0 |a Need for Optimal Design of Pharmaceutical Programs and Portfolios in Modern Medical Product Development -- Clinical Aspects of Pharmaceutical Portfolio Management -- Drug Development and the Cost of Capital -- Investment Considerations for Pharmaceutical Product Portfolios -- Challenges of Portfolio Management in Pharmaceutical Development -- Impact of Phase 2b Strategies on Optimization of Drug Development Programs -- Using Decision Analysis to Support the Design of Clinical Trials at a Program Level -- Indication Sequencing for a New Molecular Entity with Multiple Potential Oncology Indications -- Maximizing Return on Investment in Phase II Proof-of-Concept Trials -- Portfolio Optimization of Therapies and Their Predictive Biomarkers -- Dynamically Optimizing Budget Allocation for Phase 3 Drug Development Portfolios Incorporating Uncertainty in the Pipeline. 
520 |a Very little has been published on optimization of pharmaceutical portfolios. Moreover, most of the published literature comes from the commercial perspective, where probability of technical success (PoS) is treated as fixed, and not as a consequence of development strategy or design. In this book there is a strong focus on the impact of study design on PoS, and ultimately a portfolio’s value. Design options that are discussed are dose-selection strategies, adaptive design, and enrichment. Some development strategies that are examined are indication sequencing, optimal number of programs, and optimal decision criteria.     This book includes chapters written by authors with very broad backgrounds including financial, clinical, statistical, decision sciences, commercial, and regulatory. Many authors have long held executive positions and have been involved with decision making at a product or at a portfolio level. As such, it is expected that this book will attract a very broad audience, including decision makers in pharmaceutical R&D, commercial, and financial departments. The intended audience also includes portfolio planners and managers, statisticians, decision scientists, and clinicians. Early chapters describe approaches to portfolio optimization from big pharma, and venture capital standpoints, focusing on finances and processes. Later chapters present selected statistical and decision analysis methods for optimizing drug development programs and portfolios. Some methodological chapters are technical; however, with a few exceptions they require a basic knowledge of statistics by a reader. . 
590 |a Loaded electronically. 
590 |a Electronic access restricted to members of the Holy Cross Community. 
650 0 |a Operations research. 
650 0 |a Decision making. 
650 0 |a Mathematical optimization. 
650 0 |a Statistics . 
690 |a Electronic resources (E-books) 
700 1 |a Antonijevic, Zoran.  |e editor.  |4 edt  |4 http://id.loc.gov/vocabulary/relators/edt 
710 2 |a SpringerLink (Online service) 
773 0 |t Springer eBooks 
830 0 |a Springer eBook Collection. 
856 4 0 |u https://holycross.idm.oclc.org/login?auth=cas&url=https://doi.org/10.1007/978-3-319-09075-7  |3 Click to view e-book  |t 0 
907 |a .b32968735  |b 04-18-22  |c 02-26-20 
998 |a he  |b 02-26-20  |c m  |d @   |e -  |f eng  |g gw   |h 0  |i 1 
912 |a ZDB-2-SBE 
950 |a Business and Economics (Springer-11643) 
902 |a springer purchased ebooks 
903 |a SEB-COLL 
945 |f  - -   |g 1  |h 0  |j  - -   |k  - -   |l he   |o -  |p $0.00  |q -  |r -  |s b   |t 38  |u 0  |v 0  |w 0  |x 0  |y .i22100350  |z 02-26-20 
999 f f |i 76e64125-3e7d-5a6f-9d1c-ffcd629f58e3  |s 6f8dbd90-ff3c-5591-a9d6-a6431a921d64  |t 0 
952 f f |p Online  |a College of the Holy Cross  |b Main Campus  |c E-Resources  |d Online  |t 0  |e E-Book  |h Library of Congress classification  |i Elec File